Credit Suisse Sees Esperion Therapeutics Likely Acquisition, Raises PT To $100 From $41

"We are raising our TP to $100/share and believe the most likely outcome is an acquisition prior to or early in the Phase III development program (late-2015/early-2016)"
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!